Cutting-edge research, expertise in vaccine technology and a versatile platform enable Cytos Biotechnology to pursue in parallel different Immunodrug™ programs addressing important chronic disease indications. Six product candidates are currently in clinical development. Clinical proof-of-concept has been established for three vaccine candidates in the indications hypertension, smoking cessation and allergy, and the program in malignant melanoma has advanced to a further phase IIa trial after encouraging initial results were obtained in 2007. The Immunodrug™  programs in smoking cessation and Alzheimer's disease are both partnered with Novartis, whereas the Immunodrug™ collaborations with Pfizer and Pfizer Animal Health focus on undisclosed human health and animal health applications.